Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genetic testing panel

This article was originally published in The Gray Sheet

Executive Summary

HHS Secretary's advisory committee on genetic testing (SACGT) will hold its first meeting June 30 on the National Institutes of Health campus in Bethesda. Edward McCabe, MD, an NIH-funded pediatrician at the University of California at Los Angeles, chairs the 13-member panel. Other members include Centers for Disease Control and Prevention's Clinical Laboratory Improvement Advisory Committee member Patricia Charache, MD, and Joann Boughman, PhD, a member of FDA's Medical Devices Advisory Committee. Panelists will report to HHS Assistant Secretary David Satcher, who will give the group its charge June 30. SACGT will meet twice yearly and have an estimated annual budget of $130,000. HHS Secretary Donna Shalala convened the group to advise on "development, validation and regulation of genetic tests," following recommendations by two NIH panels

You may also be interested in...

Recent eMDR Change By FDA Asks Adverse Event Reporters About Third-Party Servicers

The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.

Experts: HHS Review Proposal May Free Industry From Regulatory Red Tape

Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.

Commercial Partner Sought For Nasal Spray Claimed To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts